Across
- 3. Anti-IL5 that is dosed subcutaneously every 4 weeks for the treatment of severe asthma
- 5. Chronic obstructive pulmonary disease
- 6. Rinsing mouth after ICS use can prevent this complication
- 9. A patient experiences sudden severe wheezing and difficulty speaking. Where should the patient go?
- 10. IL-4 and IL-13R agent effective for many indications, including asthma, atopic dermatitis, nasal polyps, and esophagitis
- 12. Disease of airway inflammation and bronchial hyperresponsiveness
- 14. Blood biomarker useful in assessment of biologic initiation
- 17. Therapeutic target for tezepelumab
- 19. Brand name of mometasone and formoterol combination inhaler
- 23. Common LAMA used once daily
- 25. Therapeutic class of inhaled therapy to control inflammation
- 26. Biologic studied for use in COPD in trials NOTUS and BOREAS
- 27. Long-acting beta agonist used in SMART
- 28. Exposure/environmental risk factor for COPD progression
- 29. Orally administered PDE4 inhibitor that prevents cAMP breakdown to provide anti-inflammatory effects
- 32. Lung measurement of volume of air that can be exhaled in first second of foreceful exhale
- 37. Therapeutic class of beta agonists and muscarinic antagonists
- 39. Calling the pharmacy to ensure monthly refills of maintenance inhaler can ensure good ___________
- 40. Brand name of dupilumab
- 41. Neurotransmitter that causes bronchoconstriction, mucus secretion, inflammation, and airway remodeling
- 43. Public health measure that can be used to prevent common respiratory illnesses
- 44. Anti-IgE monoclonal antibody
- 45. First inhaled corticosteroid that demonstrated effectiveness and had few systemic side effects
- 47. Medical term for shortness of breath
- 49. Exhaled nitric oxide test which serves a way to determine amount of lung inflammation
Down
- 1. Active ingredient in ProAir, Proventil, and Ventolin inhalers
- 2. Patient with acute COPD flare in the ER needs nebulized anticholinergic
- 4. Leukotriene receptor antagonist with box warning for neuropsychiatric adverse events
- 7. Evidence-based recommendations used for the management of COPD
- 8. Route of administration for corticosteroids that has been linked to serious side effects such as immunosuppression, osteoporosis, diabetes mellitus, cataracts, and an increased risk of cardiovascular disease
- 11. Biologic agent that can be given every 8 weeks during the maintenance phase
- 13. Terminology for the standard care of COPD, including an inhaled corticosteroid, long-acting beta-agonist, and long-acting muscarinic antagonist
- 15. Pulmonary function test to measure how much air can be breathed in and out
- 16. Handwritten, printed, digital, or pictorial document to help patients assess their level of asthma control and instructions if suboptimal
- 18. Brand name of budesonide and formoterol combination inhaler
- 20. Maintenance treatment approach using a single inhaler for maintenance and reliever control
- 21. Most common pathogenic species in COPD
- 22. Imbalance in the pulmonary _________ in COPD patients may lead to increased infections
- 24. Antibiotic that can be used three times per week to reduce asthma exacerbations
- 27. Brand name of benralizumab
- 30. Minimum number of months needed to assess effectiveness of a biologic for asthma
- 31. Route of administration for biologics delivered at home
- 33. Inhaler type that requires patients to make a forceful and deep inhalation
- 34. Antibiotic commonly used for bacterial exacerbations starting with "D"
- 35. Tube-like device that attaches to a metered-dose inhaler to more effectively deliver asthma medication to the lungs
- 36. Brand name of penicillin compound commonly used for COPD exacerbations
- 38. Combination ICS/LABA starting with "A"
- 42. Next step add-on for patient on LAMA/LABA that still has exacerbations + high eosinophils
- 46. Subset of asthma characterized by eosinophilic airway inflammation
- 48. Anti-inflammatory reliever; treatment with low-dose ICS and formoterol taken whenever needed to relieve asthma symptoms